Corvus Pharmaceuticals (CRVS) Price & Analysis

Compare

610 Followers

CRVS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.54 - $10.00

Previous CloseN/A

Volume202.27K

Average Volume (3M)801.73K

Market Cap

$316.17M

Enterprise Value$195.93M

Total Cash (Recent Filing)$44.21M

Total Debt (Recent Filing)$1.15M

Price to Earnings (P/E)―

Beta1.42

Next Earnings

Aug 07, 2025

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding77,114,640

10 Day Avg. Volume480,370

30 Day Avg. Volume801,727

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.62

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-9.33K

Enterprise Value/Ebitda-6.29

Forecast

1Y Price Target

$13.00

Price Target Upside201.62% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Drug EfficacyThe latest update showed that 63% of patients treated with the 200 mg BID dose achieved EASI 75, outperforming placebo benchmarks.

Future OpportunitiesPositive data in atopic dermatitis could open opportunities for soquelitinib in other immune diseases, potentially boosting CRVS shares.

Therapeutic PotentialAnalysts believe that soquelitinib could become one of the best AD therapies on the market based on the results from the latest patient cohort.

Bears Say

Financial PerformanceThe company reported no revenues and a net loss of $0.13 per diluted share, compared to consensus estimated net loss of $0.12 per share.

Investor ConfidenceThere is a lack of investor confidence that higher dose data will show improved results, contributing to the stock's decline.

Market CompetitionThe significant drop in CRVS shares is seen as an overreaction, potentially due to market disappointment with soquel's efficacy compared to Dupixent.

Corvus Pharmaceuticals News

Corvus Pharmaceuticals’ Promising Study on Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Inc. (($CRVS)) announced an update on their ongoing clinical study. Corvus Pharmaceuticals Inc. is conducting a...

1M ago

CRVS

Corvus announces IND application approved by CDE of China NMPA to start trial

Corvus Pharmaceuticals (CRVS) announced that the IND application submitted by its partner in China, Angel Pharmaceuticals, has been...

1M ago

CRVS

Corvus Pharmaceuticals Holds Annual Stockholders Meeting

Corvus Pharmaceuticals ( ($CRVS) ) has provided an update. On June 12, 2025, Corvus Pharmaceuticals held its Annual...

2M ago

CRVS

Corvus Pharmaceuticals Reports Promising Phase 1 Trial Results

Corvus Pharmaceuticals ( ($CRVS) ) has issued an announcement. On June 4, 2025, Corvus Pharmaceuticals announced interim data...

2M ago

CRVS

Corvus announces new interim data from Phase 1 trial of soquelitinib

Corvus Pharmaceuticals (CRVS) announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib...

2M ago

CRVS

Corvus Pharmaceuticals price target lowered to $11 from $12 at Mizuho

Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Corvus Pharmaceuticals (CRVS) to $11 from $12 and...

3M ago

CRVS

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

CRVS

PHAT

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Wolfspeed (WOLF) 83.21% +6.04,...

3M ago

FTI

SAP

Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings

Corvus Pharmaceuticals Inc. (($CRVS)) has held its Q1 earnings call. Read on for the main highlights of the...

3M ago

CRVS

Corvus Pharmaceuticals price target raised to $17 from $15 at Oppenheimer

Oppenheimer raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $17 from $15 and keeps an Outperform...

3M ago

CRVS

Corvus Pharmaceuticals: Promising AD Treatment Developments and Strategic Expansion Justify Buy Rating

Corvus Pharmaceuticals (CRVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday....

3M ago

CRVS

Corvus Pharmaceuticals Reports Promising Q1 2025 Results

Corvus Pharmaceuticals Inc. ( ($CRVS) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

CRVS

Corvus Pharmaceuticals Reports Positive Phase 1 Trial Results

Corvus Pharmaceuticals ( ($CRVS) ) has issued an update. On May 8, 2025, Corvus Pharmaceuticals announced interim data...

3M ago

CRVS

Corvus Pharmaceuticals reports Q1 EPS (13c), consensus (12c)

“The new soquelitinib data being presented at the Society for Investigative Dermatology annual meeting supports its potential to...

3M ago

CRVS

CRVS FAQ

What was Corvus Pharmaceuticals Inc’s price range in the past 12 months?

Corvus Pharmaceuticals Inc lowest stock price was $2.54 and its highest was $10.00 in the past 12 months.

What is Corvus Pharmaceuticals Inc’s market cap?

Corvus Pharmaceuticals Inc’s market cap is $316.17M.

When is Corvus Pharmaceuticals Inc’s upcoming earnings report date?

Corvus Pharmaceuticals Inc’s upcoming earnings report date is Aug 07, 2025 which is tomorrow.

How were Corvus Pharmaceuticals Inc’s earnings last quarter?

Corvus Pharmaceuticals Inc released its earnings results on May 08, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.01.

Is Corvus Pharmaceuticals Inc overvalued?

According to Wall Street analysts Corvus Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Corvus Pharmaceuticals Inc pay dividends?

Corvus Pharmaceuticals Inc does not currently pay dividends.

What is Corvus Pharmaceuticals Inc’s EPS estimate?

Corvus Pharmaceuticals Inc’s EPS estimate is -0.13.

How many shares outstanding does Corvus Pharmaceuticals Inc have?

Corvus Pharmaceuticals Inc has 77,114,640 shares outstanding.

What happened to Corvus Pharmaceuticals Inc’s price movement after its last earnings report?

Corvus Pharmaceuticals Inc reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went up 32.239%.

Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in CRVS

Corvus Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-100.13%

Trailing 12-Months

Asset Growth

48.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Corvus Pharmaceuticals (CRVS) Earnings & Revenues

CRVS Earnings Data >

CRVS Company Deck

CRVS Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a generally positive outlook for Corvus Pharmaceuticals, with significant net income growth, successful warrant exercises boosting cash position, and promising Phase 1 trial results for soquelitinib. Despite the increase in R&D expenses and a decrease in cash reserves, the company's financial position remains robust, supported by the recent warrant exercise.Read More>

CRVS Stock 12 Month Forecast

Average Price Target

$13.00

▲(201.62%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","18":"$18","4.5":"$4.5","13.5":"$13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.5,9,13.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.86,4.8707692307692305,5.881538461538462,6.892307692307693,7.903076923076924,8.913846153846155,9.924615384615384,10.935384615384615,11.946153846153846,12.956923076923077,13.967692307692309,14.97846153846154,15.989230769230769,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.86,4.563076923076923,5.266153846153847,5.969230769230769,6.672307692307692,7.375384615384616,8.07846153846154,8.781538461538462,9.484615384615385,10.187692307692307,10.890769230769232,11.593846153846155,12.296923076923077,{"y":13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.86,4.409230769230769,4.958461538461538,5.507692307692308,6.056923076923077,6.6061538461538465,7.155384615384616,7.704615384615385,8.253846153846155,8.803076923076924,9.352307692307694,9.901538461538463,10.45076923076923,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.18,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >